Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasms 5Small Cell Lung Carcinoma 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Advanced Cancer 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stereotactic Body Radiation Therapy 1Sarcoma 1Recurrence 1Platinum-resistant Recurrent Clear Cell Ovarian Cancer 1Pheochromocytoma 1Paraganglioma, Extra-Adrenal 1Paraganglioma 1Pancreatic Neoplasms 1NSCLC 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colonic Neoplasms 1Carcinoma, Medullary 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Malignancy 1Advanced Endometrial Cancer 1Adenocarcinoma of Lung 1

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × anlotinib × Clear all
NCT02825563 2019-05-22

A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Completed
22 enrolled

Advanced Cancer

NCT01833923 2015-10-28

ALTN

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Completed
35 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡